CM for Patients With ALD After Liver Transplant
NCT06304467 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30
Last updated 2026-04-14
Summary
Alcohol associated liver disease (ALD) refers to liver injury, such as cirrhosis, that is caused by alcohol use. It affects 2 million adults in the U.S. and is now the leading cause of cirrhosis-related hospitalizations, cirrhosis- related deaths, and liver transplantation. Alcohol use disorder (AUD), the root cause of ALD, affects 15 million Americans each year. While research studies have shown that behavioral therapy and medications specific for alcohol use have helped people overcome their alcohol use disorder, there has not been enough information related to how successful these treatments are specifically for people with ALD. This study will look at a behavioral treatment called "contingency management" (CM) that has shown to be effective with people with other substance use disorders. CM is based on the principles of operant conditioning that involves offering prize-based or monetary incentives to patients with substance use disorders to reduce substance use. This study will look at the efficacy and acceptability of CM in patients who received a liver transplant and have evidence of recurrent alcohol use.
The proposed study is a pilot randomized controlled trial of 30 patients with ALD who received a liver transplant; 15 will be randomized to receive a 10-week CM intervention while 15 will receive treatment as usual (TAU or control). Subjects will be asked to complete 12 study visits (including Screening and Baseline Visits) that will last 1 to 2 hours each depending on the visit. All visits will be completed via Zoom or by phone. Study staff will instruct participants on how to use Zoom, if necessary. During the Screening and Baseline Visits, subjects will be: 1) asked to provide a urine test and blood draw, 2) complete the SCID-5 AUD, a semi-structured interview guide for making the major DSM-5 diagnoses, 3) complete the Iowa Gambling Test which looks at decision-making skills, 4) complete a survey that looks at the subject's quality of life after liver transplant, 4) review how much alcohol the subject has consumed in the last 30 days, 5) and if the subject has received any current AUD treatments. Once the Screening and Baseline visits are completed, subjects will be randomized to either the CM group or the TAU group. During the weekly visits, subjects will be asked to provide blood and urine samples and will be asked if they have had any alcohol since their last visit. All subjects will receive $20 for completing the visits. For those in the CM group, subjects will also receive a CM reward for negative urine and/or blood tests, depending on which results we receive first-with rewards ranging from $5 to $80 depending on the week. Additionally, during weeks 1, 5, and 10, those in the CM group will also complete the Client Satisfaction Questionnaire-8 to assess client satisfaction with CM and complete a semi-structured interview about the CM protocol as well as CM acceptability and feasibility.
Conditions
- Alcohol Use Disorder
- Alcohol; Liver
- Post Liver Transplant
- Contingency Management
- Alcohol Liver Disease
Interventions
- BEHAVIORAL
-
Contingency Management
Study subjects who have received a liver transplant and have been randomized to the treatment arm will receive contingency management, a positive reinforcement behavioral treatment with escalating rewards for consecutive either negative urine and blood tests (or lower value of metabolites than the previous week for PeTH) depending on which results are received first, capped at a maximum of $80 (in the form of a gift card) at the week 10 visit.
Sponsors & Collaborators
-
Arpan A. Patel, MD
lead OTHER
Principal Investigators
-
Arpan G Patel, MD · University of California, Los Angeles
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 99 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2024-09-17
- Primary Completion
- 2026-06-01
- Completion
- 2026-09-01
Countries
- United States
Study Locations
More Related Trials
-
Efficacy of Baclofen Vs Naltrexon in Achieving & Maintaining Abstinence in Alcohol Dependence.
NCT06175507 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Alcohol Biosensor Monitoring for Alcoholic Liver Disease
NCT03533660 ·Status: COMPLETED ·Phase: NA
-
Ambulatory Alcohol Detoxification With Remote Monitoring
NCT03582150 ·Status: WITHDRAWN ·Phase: NA
-
Screening for Alcohol-related Cognitive Impairments in Cirrhotic Patients
NCT04490330 ·Status: UNKNOWN
-
Managing Alcoholism in People Who Do Not Respond to Naltrexone
NCT00115037 ·Status: COMPLETED ·Phase: PHASE4
-
CBT-I Augmentation of Medication for Drinking in AUD
NCT04581603 ·Status: TERMINATED ·Phase: PHASE4
-
Collaborative Care for Alcohol Use Disorders in the Patient-centered Medical Home
NCT02885311 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Naltrexone Treatment for Alcoholism
NCT00000438 ·Status: COMPLETED ·Phase: PHASE4
-
Clinical Study of TripleA for Treatment of Alcohol Addiction in Outpatient Care
NCT03195894 ·Status: COMPLETED ·Phase: NA
-
Treatment of Alcohol Withdrawal in Hospital Patients
NCT00249366 ·Status: COMPLETED ·Phase: PHASE4
-
A Gene by Medication Interaction to the Acute Effects of Alcohol
NCT01343628 ·Status: TERMINATED ·Phase: PHASE1
-
Abuse and Addiction in ICU
NCT02951793 ·Status: UNKNOWN
-
Can Cognitive-bias Modification Training During Inpatient Alcohol Detoxification Reduce Relapse Rates Post-discharge?
NCT02634476 ·Status: COMPLETED ·Phase: NA
-
Naltrexone for Heavy Drinking in Young Adults
NCT00568958 ·Status: COMPLETED ·Phase: PHASE4
-
Combination of Naltrexone and Baclofen for Alcohol Dependence:A Pilot Study.
NCT00614328 ·Status: COMPLETED ·Phase: PHASE1
-
Coronavirus Disease 2019 (Covid-19) Impact on Alcohol-related Liver Disease Patient Outcomes, Care and Alcohol Use
NCT05191446 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Development of a Selective ALDH2 Inhibitor to Treat AUD
NCT04311294 ·Status: WITHDRAWN ·Phase: PHASE2
-
The Effectiveness of a Smartphone Application in the Treatment of Alcohol Use Disorder
NCT03396887 ·Status: UNKNOWN ·Phase: NA
-
Naltrexone Maintenance Treatment of Alcoholism
NCT00000450 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy of Baclofen in the Treatment of Alcohol Addiction
NCT00525252 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Baclofen to Prevent Agitation in Alcohol Addicted Patients in ICU
NCT02723383 ·Status: COMPLETED ·Phase: PHASE3
-
Inpatient Alcohol Detox & Psychotherapy
NCT03988478 ·Status: COMPLETED ·Phase: NA
-
Post-Treatment Effects of Naltrexone
NCT00006449 ·Status: COMPLETED ·Phase: PHASE4
-
Intensive Referral to Al-Anon: Benefits to Concerned Others and Their Drinkers
NCT04018560 ·Status: COMPLETED ·Phase: NA
-
Drug Therapy for Alcohol Dependence in Alaska Natives (Naltrexone/Sertraline)
NCT00000451 ·Status: COMPLETED ·Phase: PHASE2